[PMID]: | 28056837 |
[Au] Autor: | Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H |
[Ad] Endereço: | Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong Province, 250012, People's Republic of China. |
[Ti] Título: | Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii. |
[So] Source: | BMC Infect Dis;17(1):19, 2017 Jan 05. |
[Is] ISSN: | 1471-2334 |
[Cp] País de publicação: | England |
[La] Idioma: | eng |
[Ab] Resumo: | BACKGROUND: A widely prevalent disease, toxoplasmosis poses serious health threats to both humans and animals; therefore, development of an ideal DNA vaccine against Toxoplasma gondii is needed eagerly. The purpose of the present study is to assess the protective efficacy of a DNA vaccine encoding the T. gondii toxofilin gene (pEGFP-toxofilin). In addition, toxofilin DNA vaccine combined with the individual adjuvants, alum or monophosphoryl lipid A (MPLA), or a mixture of alum-MPLA adjuvant were screened for their ability to enhance antibody responses. METHODS: Using bioinformatics, we analyzed the gene and amino acid sequences of the toxofilin protein, recognizing and identifying several potential linear B and T helper (Th)-1 cell epitopes. BALB/c mice were immunized three times with either toxofilin DNA vaccine alone or in combination with the adjuvants such as alum, MPLA or an alum-MPLA mixture. The systemic immune response was evaluated by cytokine, the percentage of CD4 (+) and CD8 (+) T cells and specific antibody measurement. Two weeks after the last immunization, protective efficacy was evaluated by challenging intraperitoneally with 1 × 10 tachyzoites of T. gondii or intragastrically with 20 cysts of T. gondii PRU strain. RESULTS: All experimentally immunized mice developed strong humoral and cellular immune responses compared with the control groups. Moreover, by comparison with the non-adjuvant toxofilin DNA vaccine group, adding alum adjuvant to toxofilin DNA vaccine resulted in an increase in humoral response and a skewed Th2 response. However, the MPLA adjuvant with toxofilin DNA vaccine induced significantly enhanced humoral and Th1-biased immune responses. Importantly, the co-administration of alum-MPLA adjuvant in combination with the toxofilin DNA vaccine shifted the Th2 immune response to a Th1 response compared with the alum-toxofilin group, and elicited the strongest humoral and Th1 responses among all the groups. At the same time, a longer survival time and less cyst amounts against T. gondii infection were also observed in the alum-MPLA-toxofilin group in comparison with single or no adjuvant groups. CONCLUSIONS: Toxoplasma gondii toxofilin is a promising vaccine candidate that warrants further development. Co-administration of the alum-MPLA adjuvant mixture with DNA vaccine could effectively enhance immunogenicity and strongly skew the cellular immune response towards a Th1 phenotype. |
[Mh] Termos MeSH primário: |
Proteínas de Capeamento de Actina/genética Adjuvantes Imunológicos/farmacologia Lipídeo A/análogos & derivados Proteínas de Protozoários/genética Vacinas Protozoárias/farmacologia Toxoplasmose/imunologia
|
[Mh] Termos MeSH secundário: |
Proteínas de Capeamento de Actina/imunologia Compostos de Alúmen/farmacologia Animais Formação de Anticorpos/efeitos dos fármacos Feminino Imunidade Celular Lipídeo A/imunologia Lipídeo A/farmacologia Camundongos Endogâmicos BALB C Proteínas de Protozoários/imunologia Vacinas Protozoárias/imunologia Toxoplasma/imunologia Toxoplasma/patogenicidade Toxoplasmose/prevenção & controle Vacinas de DNA/imunologia Vacinas de DNA/farmacologia
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (Actin Capping Proteins); 0 (Adjuvants, Immunologic); 0 (Alum Compounds); 0 (Lipid A); 0 (Protozoan Proteins); 0 (Protozoan Vaccines); 0 (Vaccines, DNA); 0 (toxofilin protein, Toxoplasma gondii); 34S289N54E (aluminum sulfate); MWC0ET1L2P (monophosphoryl lipid A) |
[Em] Mês de entrada: | 1709 |
[Cu] Atualização por classe: | 170904 |
[Lr] Data última revisão:
| 170904 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170107 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1186/s12879-016-2147-1 |
|
|